Hydroxycitronellal API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Hydroxycitronellal API 107-75-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Hydroxycitronellal. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Hydroxycitronellal
- Synonyms:
- 3,7-dimethyl-7-hydroxyoctan-1-al , 3,7-Dimethyl-7-hydroxyoctanal , 7-hydroxy-3,7-dimethyloctanal , 7-hydroxycitronellal , Citronellal hydrate , Cyclalia , Cyclosia , Fixol , hydroxy citronellal , Laurine , Lilyl aldehyde , Muguet synthetic , Muguettine principle , Oxydihydrocitronellal , Phixia
- Cas Number:
- 107-75-5
- DrugBank number:
- DB14187
- Unique Ingredient Identifier:
- 8SQ0VA4YUR
General Description:
Hydroxycitronellal, identified by CAS number 107-75-5, is a notable compound with significant therapeutic applications. Hydroxycitronellal is a synthetic fragrance that is widely used in many cosmetics and hygiene products such as deodorants, soaps, antiseptics, and other household items. It has the smell of lilac, lily, and lily of the valley . Hydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain only 0.1-3.6%. Sensitivity to hydroxycitronellal may be identified with a clinical patch test.
Indications:
This drug is primarily indicated for: Hydroxycitronellal is approved by the FDA for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Hydroxycitronellal undergoes metabolic processing primarily in: Studies in rabbits have shown that hydroxycitronellal is converted to two primary metabolites: reduction to the alcohol 7-hydroxycitronellol and oxidation to the carboxylic acid 7-hydroxycitronellylic acid . On average, about 50% of hydroxycitronellal is excreted as 7-hydroxycitronellylic acid which is therefore regarded as the major metabolite . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Half-life:
The half-life of Hydroxycitronellal is an important consideration for its dosing schedule: The mean elimination half-life has been found to be 3.3 h . This determines the duration of action and helps in formulating effective dosing regimens.
Volume of Distribution:
Hydroxycitronellal is distributed throughout the body with a volume of distribution of: Tmax was found to be 2.70 ± 1.36. This metric indicates how extensively the drug permeates into body tissues.
Categories:
Hydroxycitronellal is categorized under the following therapeutic classes: Cell-mediated Immunity, Increased Histamine Release, Perfume, Standardized Chemical Allergen. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Hydroxycitronellal is a type of Antimetabolites
Antimetabolites are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various diseases, particularly cancer. These compounds are structurally similar to naturally occurring metabolites essential for cellular processes such as DNA and RNA synthesis. By mimicking these metabolites, antimetabolites interfere with the normal functioning of cellular pathways, leading to inhibition of cancer cell growth and proliferation.
One of the widely used antimetabolites is methotrexate, a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, disrupting the production of DNA and RNA. This disruption impedes the growth of rapidly dividing cancer cells. Another common antimetabolite is 5-fluorouracil (5-FU), which inhibits the enzyme thymidylate synthase, thereby interfering with DNA synthesis and inhibiting cancer cell proliferation.
Antimetabolites can be classified into several subcategories based on their mechanism of action and chemical structure. These include purine and pyrimidine analogs, folic acid antagonists, and pyrimidine synthesis inhibitors. Examples of antimetabolites in these subcategories include azathioprine, cytarabine, and gemcitabine.
Despite their effectiveness, antimetabolites can exhibit certain side effects due to their interference with normal cellular processes. These side effects may include gastrointestinal disturbances, myelosuppression (reduced production of blood cells), and hepatotoxicity.
In conclusion, antimetabolites are a vital category of pharmaceutical APIs used in the treatment of various diseases, especially cancer. By mimicking natural metabolites and disrupting crucial cellular processes, these compounds effectively inhibit cancer cell growth and proliferation. However, their usage should be carefully monitored due to potential side effects.
